OLMETEC

国家: 印度尼西亚

语言: 印度尼西亚文

来源: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

产品特点 产品特点 (SPC)
22-06-2021

有效成分:

OLMESARTAN MEDOXOMIL

可用日期:

PFIZER INDONESIA - Indonesia

INN(国际名称):

OLMESARTAN MEDOXOMIL

剂量:

20 MG

药物剂型:

TABLET SALUT SELAPUT

每包单位数:

DUS, 3 BLISTER @ 10 TABLET SALUT SELAPUT

厂商:

DAICHI SANKYO EUROPE GmbH - Germany

授权日期:

2019-11-04

产品特点

                                Generic Name: Olmesartan medoxomil
Trade Name: Olmetec
®
CDS Effective Date: April 2020
Supersedes: May 2016
Approved by BPOM:
2020-0060223
Page 1 of 13
PT. PFIZER INDONESIA
LOCAL PRODUCT DOCUMENT
Generic Name: Olmesartan medoxomil
Trade Name: Olmetec
®
CDS Effective Date: April 2020
Supersedes: May 2016
NAME OF THE MEDICINAL PRODUCT
Olmetec
®
20 mg film-coated tablet
Olmetec
®
40 mg film-coated tablet
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 20 mg of olmesartan medoxomil
Each tablet contains 40 mg of olmesartan medoxomil
For excipients, see section LIST OF EXCIPIENTS
PHARMACEUTICAL FORM
Film-coated tablet.
Olmetec
®
20 mg tablets: White, circular, film-coated tablets with C14
respectively debossed
on one side.
Olmetec
®
40 mg tablets: White, oval, film-coated tablets with C15 debossed on
one side.
CLINICAL PARTICULARS
THERAPEUTIC INDICATION
Treatment of essential hypertension.
POSOLOGY AND METHOD OF ADMINISTRATION
ADULTS
The recommended starting dose of olmesartan medoxomil is 10 mg once
daily. In patients
whose blood pressure is not adequately controlled at this dose, the
dose of olmesartan
medoxomil may be increased to 20 mg once daily as the optimal dose. If
additional blood
pressure reduction is required, olmesartan medoxomil dose may be
increased to a maximum
of 40 mg daily or hydrochlorothiazide therapy may be added.
DISETUJUI OLEH BPOM: 21/04/2021
ID REG: EREG10024112000528 - EREG10024112000529
Generic Name: Olmesartan medoxomil
Trade Name: Olmetec
®
CDS Effective Date: April 2020
Supersedes: May 2016
Approved by BPOM:
2020-0060223
Page 2 of 13
The antihypertensive effect of olmesartan medoxomil is substantially
present within 2 weeks
of initiating therapy and is maximal by about 8 weeks after initiating
therapy. This should be
borne in mind when considering changing the dose regimen for any
patient.
In order to assist compliance, it is recommended that Olmetec
®
tablets be taken at about the
same time each day, with or without food, for example at breakfast
time.
ELDERLY
The 
                                
                                阅读完整的文件
                                
                            

搜索与此产品相关的警报

查看文件历史